Michelson Diagnostics
Financials
Estimates*
GBP | 2011 | 2012 | 2013 | 2014 | 2015 |
---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | 1.3m | <1m |
% growth | - | 60 % | 65 % | 89 % | (50 %) |
EBITDA | (<1m) | (1.6m) | (2.3m) | (1.8m) | (2.5m) |
% EBITDA margin | (329 %) | (391 %) | (342 %) | (143 %) | (404 %) |
Profit | (<1m) | (1.4m) | (2.1m) | (1.8m) | (2.5m) |
% profit margin | (297 %) | (349 %) | (321 %) | (145 %) | (404 %) |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Seed | ||
N/A | $1.1m | Seed | |
N/A | £1.7m | Series A | |
£610k | Seed | ||
N/A | $3.3m | Series A | |
€2.5m | Series B | ||
Total Funding | AUD15.8m |
Recent News about Michelson Diagnostics
EditVivoSight operates in the medical imaging sector, specializing in advanced skin imaging technology. The company serves dermatologists, clinical researchers, and healthcare providers by offering a powerful and versatile imaging tool known as VivoSight OCT. This technology provides objective measurements of various skin parameters, including epidermal thickness, blood flow, and collagen density, which are crucial for both research and clinical applications. The market for VivoSight includes clinical settings focused on skin health, non-melanoma skin cancer, and transdermal drug delivery, among others. The business model revolves around selling their imaging systems and companion products, as well as providing training and support services. Revenue is generated through direct sales, regulatory consulting, and ongoing customer support.
Keywords: skin imaging, dermatology, OCT technology, epidermal thickness, blood flow, collagen density, clinical research, non-melanoma skin cancer, transdermal drug delivery, healthcare providers.